These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10534719)

  • 1. Abciximab (ReoPro) removal with a hemoconcentrator during cardiopulmonary bypass.
    Lemmer JH
    J Thorac Cardiovasc Surg; 1999 Nov; 118(5):980-1. PubMed ID: 10534719
    [No Abstract]   [Full Text] [Related]  

  • 2. Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator.
    Steinhubl SR; Moore SA; Lincoff AM
    J Thorac Cardiovasc Surg; 2000 Feb; 119(2):401-2. PubMed ID: 10649221
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor.
    Weisman HF; Schaible TF; Jordan RE; Cabot CF; Anderson KM
    Biochem Soc Trans; 1995 Nov; 23(4):1051-7. PubMed ID: 8654680
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties.
    Peter K; Schwarz M; Bode C
    Circulation; 2002 May; 105(21):E180-1. PubMed ID: 12034670
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute severe thrombocytopenia after treatment with ReoPro (abciximab).
    Butler R; Hubner PJ
    Heart; 2000 Apr; 83(4):E5. PubMed ID: 10722557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 8. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
    Exaire JE; Lincoff AM
    J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
    [No Abstract]   [Full Text] [Related]  

  • 9. The clinical role of platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease.
    Lefkovits J; Topol EJ
    Cleve Clin J Med; 1996; 63(3):181-9. PubMed ID: 8665658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 12. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 13. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
    Bright JM; Dowers K; Powers BE
    Vet Ther; 2003; 4(1):35-46. PubMed ID: 12756634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of recurrent thrombocytopenia due to abciximab.
    Sharma V; Mascarenhas D
    J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816
    [No Abstract]   [Full Text] [Related]  

  • 17. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET
    J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
    Coller BS; Anderson KM; Weisman HF
    Haemostasis; 1996 Oct; 26 Suppl 4():285-93. PubMed ID: 8979134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ; Barr LA; Burchenal JE; Katz S; George BS; Jones AA; Cohen ED; Gainey PC; White HJ; Cheek HB; Moses JW; Moliterno DJ; Effron MB; Topol EJ
    Circulation; 1998 Aug; 98(8):734-41. PubMed ID: 9727542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Nursing; 1999 Dec; 29(12):34-9; quiz 40. PubMed ID: 10797693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.